EurekaMag.com logo
+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Symptom improvement in patients with onychomycosis receiving oral antifungal therapy



Symptom improvement in patients with onychomycosis receiving oral antifungal therapy



Southern Medical Journal 95(11): 1359-1360




(PDF emailed within 1 workday: $29.90)

Accession: 047505747

Download citation: RISBibTeXText

PMID: 12540014



Related references

Evaluation of improvement of onychomycosis in HIV-infected patients after initiation of combined antiretroviral therapy without antifungal treatment. Mycoses 58(9): 516-521, 2016

Improvement of onychomycosis without antifungal therapy after initiation of highly active anti-retroviral therapy (HAART) in an HIV-infected patient. Japanese Journal of Infectious Diseases 52(6): 245-246, 2000

Improvement of onychomycosis without antifungal therapy after initiation of highly active anti-retroviral therapy (HAART) in an HIV-infected patient. Japanese Journal of Infectious Diseases 52(6): 245-246, 1999

Factors that may affect the response of onychomycosis to oral antifungal therapy. Australasian Journal of Dermatology 39(4): 222-224, 1998

Oral candidiasis Species identification and their antifungal susceptibility pattern in cancer patients receiving radiation therapy. Journal of Radiotherapy in Practice 12(02): 100-104, 2013

Review: oral antifungal therapy has low risk for adverse events in superficial dermatophytosis and onychomycosis. Acp Journal Club 148(1): 14-14, 2008

Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. American Journal of Gastroenterology 101(5): 1057-1065, 2006

Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. Annals of Internal Medicine 135(6): 412-422, 2001

Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Annals of Internal Medicine 135(6): 412-422, 2001

Evaluation of in vitro resistance in patients with onychomycosis who fail antifungal therapy. Dermatology 207(4): 375-380, 2003

Symptoms of hormonal therapy and social support: Is there a connection? Comparison of symptom severity, symptom interference and social support among breast cancer patients receiving and not receiving adjuvant hormonal treatment. European Journal of Oncology Nursing 19(3): 260-267, 2016

Cognitive and behavioral changes related to symptom improvement among patients with a mood disorder receiving intensive cognitive-behavioral therapy. Journal of Psychiatric Practice 15(2): 95-102, 2009

Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome. Journal of Antimicrobial ChemoTherapy 41(3): 373-380, 1998

Longitudinal monitoring of CYP3A activity in patients receiving 3 cycles of itraconazole pulse therapy for onychomycosis. Journal of Clinical Pharmacy and Therapeutics 39(2): 181-185, 2014

Oral antifungal agents for onychomycosis. Lancet 351(9102): 541-542, 1998